Ngrazier 10615481cyclo

provided by InfoChem.

STRUCTURE FILE UPDATES: 4 OCT 2005 HIGHEST RN 864494-87-1
DICTIONARY FILE UPDATES: 4 OCT 2005 HIGHEST RN 864494-87-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.

****
* *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
* *
****

Structure search iteration limits have been increased. See HELP SLIMITS for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/DBSS/registryss.html

=>
Uploading C:\Program Files\Stnexp\Queries\10615481cycloalk.str



chain nodes :
6 13 14 15 16 18
ring nodes :
1 2 3 4 5 7 8 9 10 11 12 17 19 20 21 22
chain bonds :
1-6 2-13 3-15 6-7 13-14 15-16 15-18 16-17

Ngrazier 10615481cyclo

ring bonds :
1-2 1-5 2-3 3-4 4-5 7-8 7-12 8-9 9-10 10-11 11-12 17-19 17-22 19-20 20-21
21-22
exact/norm bonds :
1-2 1-5 1-6 2-3 2-13 3-4 4-5 6-7 13-14 15-16 15-18 16-17 17-19 17-22 19-20
20-21 21-22
exact bonds :
3-15
normalized bonds :
7-8 7-12 8-9 9-10 10-11 11-12

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:CLASS 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom
12:Atom 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:Atom 18:CLASS 19:Atom 20:Atom
21:Atom 22:Atom

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1
SAMPLE SEARCH INITIATED 15:47:12 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 24 TO ITERATE

100.0% PROCESSED 24 ITERATIONS 1 ANSWERS
SEARCH TIME: 00.00.01

Ngrazier 10615481cyclo

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 187 TO 773
PROJECTED ANSWERS: 1 TO 80

L2 1 SEA SSS SAM L1

=> s l1 full
FULL SEARCH INITIATED 15:47:18 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 394 TO ITERATE

100.0% PROCESSED 394 ITERATIONS 27 ANSWERS
SEARCH TIME: 00.00.01

L3 27 SEA SSS FUL L1

=> fil caplus
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 161.33 161.54

FILE 'CAPLUS' ENTERED AT 15:47:24 ON 05 OCT 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 5 Oct 2005 VOL 143 ISS 15
FILE LAST UPDATED: 4 Oct 2005 (20051004/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l3
L4 2 L3

=> d ed abs ibib hitstr 1-2

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 19 Jul 2002
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention concerns novel 2-arylimino-2,3-dihydrothiazole derivs. I and their racemates, enantiomers, combinations, and salts [wherein R1 = (un)substituted, particularly amino-substituted alk(en/yn)yl, (hetero)aryl, aralkyl, cycloalkyl, etc.; R2 = (un)substituted carbocyclic or heterocyclic aryl; R3 = alkyl, adamantyl, (un)substituted (hetero)aryl or (hetero)aralkyl, (un)substituted carbamoyl; R4 = H, alkyl, (un)substituted (hetero)aralkyl, etc.]. Also disclosed are methods of their preparation and their use as medicines, in particular for treating a wide variety of pathol. conditions or diseases involving somatostatin receptors. In particular, these pathol. conditions include acromegaly, pituitary adenoma, endocrine gastroenteropancreatic tumors (including carcinoid syndrome), and gastrointestinal bleeding. Examples include a few detailed syntheses, a listing of over 2800 characterized invention compds., and various precursor prepns. For instance, 4-H2NC6H4CH2CH2NH2 was bound to Wang resin p-nitrophenylcarbonate (at the aliphatic amino group), and the resin-bound amine reacted sequentially with PhCH2CH2NCS, bromopyruvic acid, and 4-ClC6H4CH2NH2 to give, after acidic cleavage, (Z)-isomeric title compound II. Twenty selected compds. I, including III.2HCl, inhibited binding of [125I-Tyr11]SRIF-14 to human somatostatin receptors in vitro with Ki < 200 nM.

ACCESSION NUMBER: 2002:539670 CAPLUS
DOCUMENT NUMBER: 137:93746
TITLE: 2-Arylimino-2,3-dihydrothiazoles, processes for their preparation, and their use as somatostatin receptor ligands
INVENTOR(S): Moinet, Christophe; Sackur, Carole; Thurieau, Christophe
PATENT ASSIGNEE(S): Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.), Fr.
SOURCE: PCT Int. Appl., 465 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002055510	A1	20020718	WO 2002-FR93	20020111
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
FR 2819508	A1	20020719	FR 2001-396	20010112
FR 2819508	B1	20050121		
CA 2434203	AA	20020718	CA 2002-2434203	20020111
EP 1353912	A1	20031022	EP 2002-700318	20020111

EP 1353912	B1	20050824				
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR						
BR 2002006407	A	20040106	BR 2002-6407			20020111
JP 2004530643	T2	20041007	JP 2002-556180			20020111
ZA 2003005100	A	20040827	ZA 2003-5100			20030630
NO 2003003120	A	20030911	NO 2003-3120			20030708
PRIORITY APPLN. INFO.:			FR 2001-396		A	20010112
			WO 2002-FR93		W	20020111

OTHER SOURCE(S): MARPAT 137:93746

IT **322743-77-1P 322743-89-5P 322743-90-8P**
322743-92-0P 322744-04-7P 322744-05-8P
322744-07-0P 322744-19-4P 322744-20-7P
322744-22-9P 322744-34-3P 322744-35-4P
322744-37-6P 322744-49-0P 322744-50-3P
322747-60-4P 322747-74-0P 322747-88-6P
322748-02-7P 322748-30-1P 322748-31-2P
322748-50-5P 322748-51-6P 322748-70-9P
322748-71-0P 322748-90-3P 322748-91-4P
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of (arylimino)dihydrothiazoles as somatostatin receptor ligands)

RN 322743-77-1 CAPLUS
CN 4-Thiazolecarboxamide, 3-(4-aminobutyl)-N-cyclohexyl-2,3-dihydro-2-(phenylimino)- (9CI) (CA INDEX NAME)



RN 322743-89-5 CAPLUS
CN 4-Thiazolecarboxamide, 3-(4-aminobutyl)-N-[4-(1,1-dimethylethyl)cyclohexyl]-2,3-dihydro-2-(phenylimino)- (9CI) (CA INDEX NAME)



RN 322743-90-8 CAPLUS
CN 4-Thiazolecarboxamide, 3-(4-aminobutyl)-N-(2,3-dihydro-1H-inden-2-yl)-2,3-dihydro-2-(phenylimino)- (9CI) (CA INDEX NAME)



RN 322743-92-0 CAPLUS
CN 4-Thiazolecarboxamide, 3-(4-aminobutyl)-N-cyclohexyl-2,3-dihydro-2-[[2-(1-methylethyl)phenyl]imino]- (9CI) (CA INDEX NAME)



RN 322744-04-7 CAPLUS
CN 4-Thiazolecarboxamide, 3-(4-aminobutyl)-N-[4-(1,1-dimethylethyl)cyclohexyl]-2,3-dihydro-2-[[2-(1-methylethyl)phenyl]imino]- (9CI) (CA INDEX NAME)



RN 322744-05-8 CAPLUS
CN 4-Thiazolecarboxamide, 3-(4-aminobutyl)-N-(2,3-dihydro-1H-inden-2-yl)-2,3-dihydro-2-[[2-(1-methylethyl)phenyl]imino]- (9CI) (CA INDEX NAME)



RN 322744-07-0 CAPLUS
CN 4-Thiazolecarboxamide, 3-(4-aminobutyl)-N-cyclohexyl-2,3-dihydro-2-(1-naphthalenylimino)- (9CI) (CA INDEX NAME)



RN 322744-19-4 CAPLUS
CN 4-Thiazolecarboxamide, 3-(4-aminobutyl)-N-[4-(1,1-dimethylethyl)cyclohexyl]-2,3-dihydro-2-(1-naphthalenylimino)- (9CI) (CA INDEX NAME)



RN 322744-20-7 CAPLUS
CN 4-Thiazolecarboxamide, 3-(4-aminobutyl)-N-(2,3-dihydro-1H-inden-2-yl)-2,3-dihydro-2-(1-naphthalenylimino)- (9CI) (CA INDEX NAME)



RN 322744-22-9 CAPLUS
CN 4-Thiazolecarboxamide, 3-(4-aminobutyl)-2-[(4-chlorophenyl)imino]-N-cyclohexyl-2,3-dihydro- (9CI) (CA INDEX NAME)



RN 322744-34-3 CAPLUS
CN 4-Thiazolecarboxamide, 3-(4-aminobutyl)-2-[(4-chlorophenyl)imino]-N-[4-(1,1-dimethylethyl)cyclohexyl]-2,3-dihydro- (9CI) (CA INDEX NAME)



RN 322744-35-4 CAPLUS
CN 4-Thiazolecarboxamide, 3-(4-aminobutyl)-2-[(4-chlorophenyl)imino]-N-(2,3-dihydro-1H-inden-2-yl)-2,3-dihydro- (9CI) (CA INDEX NAME)



RN 322744-37-6 CAPLUS
CN 4-Thiazolecarboxamide, 3-(4-aminobutyl)-N-cyclohexyl-2,3-dihydro-2-[[3-(trifluoromethyl)phenyl]imino]- (9CI) (CA INDEX NAME)



RN 322744-49-0 CAPLUS
CN 4-Thiazolecarboxamide, 3-(4-aminobutyl)-N-[4-(1,1-dimethylethyl)cyclohexyl]-2,3-dihydro-2-[[3-(trifluoromethyl)phenyl]imino]- (9CI) (CA INDEX NAME)



RN 322744-50-3 CAPLUS
CN 4-Thiazolecarboxamide, 3-(4-aminobutyl)-N-(2,3-dihydro-1H-inden-2-yl)-2,3-dihydro-2-[[3-(trifluoromethyl)phenyl]imino]- (9CI) (CA INDEX NAME)



RN 322747-60-4 CAPLUS
CN 4-Thiazolecarboxamide, 3-(6-aminohexyl)-2,3-dihydro-2-[(3-nitrophenyl)imino]-N-(1,2,3,4-tetrahydro-1-naphthalenyl)- (9CI) (CA INDEX NAME)



RN 322747-74-0 CAPLUS
CN 4-Thiazolecarboxamide, 3-(6-aminohexyl)-2,3-dihydro-2-[(4-phenoxyphenyl)imino]-N-(1,2,3,4-tetrahydro-1-naphthalenyl)- (9CI) (CA INDEX NAME)



RN 322747-88-6 CAPLUS
CN 4-Thiazolecarboxamide, 3-(6-aminohexyl)-2,3-dihydro-2-[[4-(1-piperidinylsulfonyl)phenyl]imino]-N-(1,2,3,4-tetrahydro-1-naphthalenyl)- (9CI) (CA INDEX NAME)

PAGE 1-A





RN 322748-02-7 CAPLUS
CN 4-Thiazolecarboxamide, 3-(6-aminohexyl)-2-[(3-bromophenyl)imino]-2,3-dihydro-N-(1,2,3,4-tetrahydro-1-naphthalenyl)- (9CI) (CA INDEX NAME)



RN 322748-30-1 CAPLUS
CN 4-Thiazolecarboxamide, 3-(4-aminobutyl)-2-[(3,5-dimethylphenyl)imino]-2,3-dihydro-N-(1,2,3,4-tetrahydro-1-naphthalenyl)- (9CI) (CA INDEX NAME)



RN 322748-31-2 CAPLUS
CN 4-Thiazolecarboxamide, 3-(4-aminobutyl)-2-[(3,5-dimethylphenyl)imino]-N-9H-fluoren-9-yl-2,3-dihydro- (9CI) (CA INDEX NAME)



RN 322748-50-5 CAPLUS
CN 4-Thiazolecarboxamide, 3-(4-aminobutyl)-2,3-dihydro-2-(1-naphthalenylimino)-N-(1,2,3,4-tetrahydro-1-naphthalenyl)- (9CI) (CA INDEX NAME)



RN 322748-51-6 CAPLUS
CN 4-Thiazolecarboxamide, 3-(4-aminobutyl)-N-9H-fluoren-9-yl-2,3-dihydro-2-(1-naphthalenylimino)- (9CI) (CA INDEX NAME)



RN 322748-70-9 CAPLUS
CN 4-Thiazolecarboxamide, 3-(5-aminopentyl)-2-[(3,5-dimethylphenyl)imino]-2,3-dihydro-N-(1,2,3,4-tetrahydro-1-naphthalenyl)- (9CI) (CA INDEX NAME)



RN 322748-71-0 CAPLUS
CN 4-Thiazolecarboxamide, 3-(5-aminopentyl)-2-[(3,5-dimethylphenyl)imino]-N-9H-fluoren-9-yl-2,3-dihydro- (9CI) (CA INDEX NAME)



RN 322748-90-3 CAPLUS
CN 4-Thiazolecarboxamide, 3-(5-aminopentyl)-2,3-dihydro-2-(1-naphthalenylimino)-N-(1,2,3,4-tetrahydro-1-naphthalenyl)- (9CI) (CA INDEX NAME)



RN 322748-91-4 CAPLUS
CN 4-Thiazolecarboxamide, 3-(5-aminopentyl)-N-9H-fluoren-9-yl-2,3-dihydro-2-(1-naphthalenylimino)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN
ED Entered STN: 02 Feb 2001
GI



I



II

AB The invention concerns novel 2-arylimino-2,3-dihydrothiazole derivs. I and their racemates, enantiomers, combinations, and salts [wherein R1 = (un)substituted, particularly amino-substituted alk(en/yn)yl, (hetero)aryl, aralkyl, cycloalkyl, etc.; R2 = (un)substituted carbocyclic or heterocyclic aryl; R3 = alkyl, adamantyl, (un)substituted (hetero)aryl or (hetero)aralkyl, (un)substituted carbamoyl; R4 = H, alkyl, (un)substituted (hetero)aralkyl, etc.]. Also disclosed are methods of their preparation and their use as medicines, in particular for treating a wide variety of pathol. conditions or diseases involving somatostatin receptors. In particular, these pathol. conditions include acromegaly, pituitary adenoma, endocrine gastroenteropancreatic tumors (including the carcinoid syndrome), and gastrointestinal bleeding. Examples include 6 detailed syntheses, a listing of over 2800 characterized invention compds., and various precursor prepns. For instance, 4-H2NC6H4CH2CH2NH2 was bound to Wang resin p-nitrophenylcarbonate (at the aliphatic amino group), and the resin-bound amine reacted sequentially with PhCH2CH2NCS, bromopyruvic acid, and 4-ClC6H4CH2NH2 to give, after acidic cleavage, (Z)-isomeric title compound II. Ten selected compds. I inhibited binding of [125I-Tyr11]SRIF-14 to human somatostatin receptors in vitro with Ki < 200 nM.

ACCESSION NUMBER: 2001:78374 CAPLUS
DOCUMENT NUMBER: 134:147596
TITLE: 2-Arylimino-2,3-dihydrothiazoles, processes for their preparation, and their use as somatostatin receptor ligands
INVENTOR(S): Moinet, Christophe; Sackur, Carole; Thurieau, Christophe
PATENT ASSIGNEE(S): Societe de Conseils de Recherches et d'Applications Scientifiques (S.C.R.A.S, Fr.
SOURCE: PCT Int. Appl., 428 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: French

FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001007424	A1	20010201	WO 2000-FR2095	20000721
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
FR 2796643	A1	20010126	FR 1999-9496	19990722
FR 2796643	B1	20050429		
CA 2382940	AA	20010201	CA 2000-2382940	20000721
BR 2000012647	A	20020409	BR 2000-12647	20000721
EP 1202980	A1	20020508	EP 2000-958575	20000721
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
JP 2003505453	T2	20030212	JP 2001-512509	20000721
NZ 516599	A	20040130	NZ 2000-516599	20000721
AU 782187	B2	20050707	AU 2000-70053	20000721
US 6727269	B1	20040427	US 2002-31429	20020115
NO 2002000314	A	20020306	NO 2002-314	20020121
PRIORITY APPLN. INFO.:			FR 1999-9496 A	19990722
			WO 2000-FR2095 W	20000721

OTHER SOURCE(S): MARPAT 134:147596
IT **322743-77-1P 322743-89-5P 322743-90-8P**
322743-92-0P 322744-04-7P 322744-05-8P
322744-07-0P 322744-19-4P 322744-20-7P
322744-22-9P 322744-34-3P 322744-35-4P
322744-37-6P 322744-49-0P 322744-50-3P
322747-60-4P 322747-74-0P 322747-88-6P
322748-02-7P 322748-30-1P 322748-31-2P
322748-50-5P 322748-51-6P 322748-70-9P
322748-71-0P 322748-90-3P 322748-91-4P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of (arylimino)dihydrothiazoles as somatostatin receptor ligands)
RN 322743-77-1 CAPLUS
CN 4-Thiazolecarboxamide, 3-(4-aminobutyl)-N-cyclohexyl-2,3-dihydro-2-(phenylimino)- (9CI) (CA INDEX NAME)



RN 322743-89-5 CAPLUS
CN 4-Thiazolecarboxamide, 3-(4-aminobutyl)-N-[4-(1,1-dimethylethyl)cyclohexyl]-2,3-dihydro-2-(phenylimino)- (9CI) (CA INDEX NAME)



RN 322743-90-8 CAPLUS
CN 4-Thiazolecarboxamide, 3-(4-aminobutyl)-N-(2,3-dihydro-1H-inden-2-yl)-2,3-dihydro-2-(phenylimino)- (9CI) (CA INDEX NAME)



RN 322743-92-0 CAPLUS
CN 4-Thiazolecarboxamide, 3-(4-aminobutyl)-N-cyclohexyl-2,3-dihydro-2-[[2-(1-methylethyl)phenyl]imino]- (9CI) (CA INDEX NAME)



RN 322744-04-7 CAPLUS
CN 4-Thiazolecarboxamide, 3-(4-aminobutyl)-N-[4-(1,1-dimethylethyl)cyclohexyl]-2,3-dihydro-2-[[2-(1-methylethyl)phenyl]imino]- (9CI) (CA INDEX NAME)



RN 322744-05-8 CAPLUS
CN 4-Thiazolecarboxamide, 3-(4-aminobutyl)-N-(2,3-dihydro-1H-inden-2-yl)-2,3-dihydro-2-[[2-(1-methylethyl)phenyl]imino]- (9CI) (CA INDEX NAME)



RN 322744-07-0 CAPLUS
CN 4-Thiazolecarboxamide, 3-(4-aminobutyl)-N-cyclohexyl-2,3-dihydro-2-(1-naphthalenylimino)- (9CI) (CA INDEX NAME)



RN 322744-19-4 CAPLUS
CN 4-Thiazolecarboxamide, 3-(4-aminobutyl)-N-[4-(1,1-dimethylethyl)cyclohexyl]-2,3-dihydro-2-(1-naphthalenylimino)- (9CI) (CA INDEX NAME)



RN 322744-20-7 CAPLUS
CN 4-Thiazolecarboxamide, 3-(4-aminobutyl)-N-(2,3-dihydro-1H-inden-2-yl)-2,3-dihydro-2-(1-naphthalenylimino)- (9CI) (CA INDEX NAME)



RN 322744-22-9 CAPLUS
CN 4-Thiazolecarboxamide, 3-(4-aminobutyl)-2-[(4-chlorophenyl)imino]-N-cyclohexyl-2,3-dihydro- (9CI) (CA INDEX NAME)



RN 322744-34-3 CAPLUS
CN 4-Thiazolecarboxamide, 3-(4-aminobutyl)-2-[(4-chlorophenyl)imino]-N-[4-(1,1-dimethylethyl)cyclohexyl]-2,3-dihydro- (9CI) (CA INDEX NAME)



RN 322744-35-4 CAPLUS
CN 4-Thiazolecarboxamide, 3-(4-aminobutyl)-2-[(4-chlorophenyl)imino]-N-(2,3-dihydro-1H-inden-2-yl)-2,3-dihydro- (9CI) (CA INDEX NAME)



RN 322744-37-6 CAPLUS
CN 4-Thiazolecarboxamide, 3-(4-aminobutyl)-N-cyclohexyl-2,3-dihydro-2-[[3-(trifluoromethyl)phenyl]imino]- (9CI) (CA INDEX NAME)



RN 322744-49-0 CAPLUS
CN 4-Thiazolecarboxamide, 3-(4-aminobutyl)-N-[4-(1,1-dimethylethyl)cyclohexyl]-2,3-dihydro-2-[[3-(trifluoromethyl)phenyl]imino]- (9CI) (CA INDEX NAME)



RN 322744-50-3 CAPLUS
CN 4-Thiazolecarboxamide, 3-(4-aminobutyl)-N-(2,3-dihydro-1H-inden-2-yl)-2,3-dihydro-2-[[3-(trifluoromethyl)phenyl]imino]- (9CI) (CA INDEX NAME)



RN 322747-60-4 CAPLUS
CN 4-Thiazolecarboxamide, 3-(6-aminohexyl)-2,3-dihydro-2-[(3-nitrophenyl)imino]-N-(1,2,3,4-tetrahydro-1-naphthalenyl)- (9CI) (CA INDEX NAME)



RN 322747-74-0 CAPLUS
CN 4-Thiazolecarboxamide, 3-(6-aminohexyl)-2,3-dihydro-2-[(4-phenoxyphenyl)imino]-N-(1,2,3,4-tetrahydro-1-naphthalenyl)- (9CI) (CA INDEX NAME)



RN 322747-88-6 CAPLUS
CN 4-Thiazolecarboxamide, 3-(6-aminohexyl)-2,3-dihydro-2-[[4-(1-piperidinylsulfonyl)phenyl]imino]-N-(1,2,3,4-tetrahydro-1-naphthalenyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 322748-02-7 CAPLUS
CN 4-Thiazolecarboxamide, 3-(6-aminohexyl)-2-[(3-bromophenyl)imino]-2,3-dihydro-N-(1,2,3,4-tetrahydro-1-naphthalenyl)- (9CI) (CA INDEX NAME)



RN 322748-30-1 CAPLUS
CN 4-Thiazolecarboxamide, 3-(4-aminobutyl)-2-[(3,5-dimethylphenyl)imino]-2,3-dihydro-N-(1,2,3,4-tetrahydro-1-naphthalenyl)- (9CI) (CA INDEX NAME)



RN 322748-31-2 CAPLUS
CN 4-Thiazolecarboxamide, 3-(4-aminobutyl)-2-[(3,5-dimethylphenyl)imino]-N-9H-fluoren-9-yl-2,3-dihydro- (9CI) (CA INDEX NAME)



RN 322748-50-5 CAPLUS
CN 4-Thiazolecarboxamide, 3-(4-aminobutyl)-2,3-dihydro-2-(1-naphthalenylimino)-N-(1,2,3,4-tetrahydro-1-naphthalenyl)- (9CI) (CA INDEX NAME)



RN 322748-51-6 CAPLUS
CN 4-Thiazolecarboxamide, 3-(4-aminobutyl)-N-9H-fluoren-9-yl-2,3-dihydro-2-(1-naphthalenylimino)- (9CI) (CA INDEX NAME)



RN 322748-70-9 CAPLUS
CN 4-Thiazolecarboxamide, 3-(5-aminopentyl)-2-[(3,5-dimethylphenyl)imino]-2,3-dihydro-N-(1,2,3,4-tetrahydro-1-naphthalenyl)- (9CI) (CA INDEX NAME)



RN 322748-71-0 CAPLUS
CN 4-Thiazolecarboxamide, 3-(5-aminopentyl)-2-[(3,5-dimethylphenyl)imino]-N-9H-fluoren-9-yl-2,3-dihydro- (9CI) (CA INDEX NAME)



RN 322748-90-3 CAPLUS
CN 4-Thiazolecarboxamide, 3-(5-aminopentyl)-2,3-dihydro-2-(1-naphthalenylimino)-N-(1,2,3,4-tetrahydro-1-naphthalenyl)- (9CI) (CA INDEX NAME)



RN 322748-91-4 CAPLUS
CN 4-Thiazolecarboxamide, 3-(5-aminopentyl)-N-9H-fluoren-9-yl-2,3-dihydro-2-(1-naphthalenylimino)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

Ngrazier 10615481cyclo

=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	10.33	171.87

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-1.46	-1.46

STN INTERNATIONAL LOGOFF AT 15:47:57 ON 05 OCT 2005